达格列净治疗射血分数降低心衰的成本效益分析
基于DAPA-HF试验的Markov队列模型,评估达格列净联合标准治疗用于慢性HFrEF患者的成本效益。
要点
- 成本效益在有无糖尿病及轻中度健康状态受损患者中相似。
核心结论
- 达格列净联合标准治疗对HFrEF患者具有中等成本效益价值。
- 需更多死亡获益幅度数据以提高成本效益估计的精确性。
研究设计与样本
- Markov队列成本效益模型,参数来源于DAPA-HF试验及其他已发表文献。
- 纳入HFrEF患者,按糖尿病状态和心衰所致健康状态受损程度分为亚组。
主要发现
- 达格列净较标准治疗平均增加0.78生命年和0.46质量调整生命年。
- 有无糖尿病及轻中度健康状态受损患者的每QALY成本相似。
- 成本效益对死亡率效应估计和治疗有效持续时间最敏感。
临床怎么用
- 达格列净联合标准治疗可作为HFrEF患者具有中等成本效益价值的选择。
- 临床决策需结合药品价格及患者糖尿病状态和健康状态受损程度综合考量。
局限性
- 成本效益估计对死亡率效应幅度敏感,需更多数据提高精确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, dapagliflozin was shown to reduce cardiovascular mortality and hospitalizations due to heart failure while improving patient-reported health status. However, the cost-effectiveness of adding dapagliflozin therapy to standard of care (SOC) is unknown. OBJECTIVE: To estimate the cost-effectiveness of dapagliflozin therapy among patients with chronic heart failure with reduced ejection fraction (HFrEF). DESIGN, SETTING, AND PARTICIPANTS: This Markov cohort cost-effectiveness model used estimates of therapy effectiveness, transition probabilities, and utilities from the DAPA-HF trial and other published literature. Costs were derived from published sources. Patients with HFrEF included subgroups based on diabetes status and health status impairment due to heart failure. We compiled parameters from the literature including DAPA-HF, on which our model is based, and many other sources from December 2019 to February 27, 2021. We performed our analysis in February 2021. EXPOSURES: Dapagliflozin or SOC. MAIN OUTCOMES AND MEASURES: Hospitalizations for heart failure, life-years, quality-adjusted life-years (QALYs), costs, and the cost per QALY gained (incremental cost-effectiveness ratio). RESULTS: In the model, dapagliflozin therapy yielded a mean of 0.78 additional life-years and 0.46 additional QALYs compared with SOC at an incremental cost of $38 212, resulting in a cost per QALY gained of $83 650. The cost per QALY was similar for patients with or without diabetes and for patients with mild or moderate impairment of health status due to heart failure. The cost-effectiveness was most sensitive to estimates of the effect on mortality and duration of therapy effectiveness. If the cost of dapagliflozin decreased from $474 to $270 (43% decline), the cost per QALY gained would drop below $50 000. CONCLUSIONS AND RELEVANCE: These findings suggest that dapagliflozin provides intermediate value compared with SOC, based on American College of Cardiology/American Heart Association benchmarks. Additional data regarding the magnitude of mortality reduction would improve the precision of cost-effectiveness estimates.
引用
- Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021. PMID: 34037681. doi:10.1001/jamacardio.2021.1437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。